Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Ups Ante In Triple COPD Therapy Race But Payers Wary

Executive Summary

GSK is hoping its decision to bring forward the US filing of its triple combination therapy for patients with COPD will ensure it is the first to launch. But while physicians are keen to see it on the market, payers are wary.

You may also be interested in...



Strong 2Q And Fresh UK Investment Signal Few Brexit Blues at GSK

GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.

Novartis's FLAME Rockets LAMA/LABAs Into COPD Limelight At GSK's Expense

Novartis's recent publication of data from its FLAME study comparing its Ultibro Breezhaler with GSK's Advair/Seretide in reducing COPD exacerbations could lead to a change in guidelines to favor LAMA/LABAs over ICS/LABA products in patients with severe COPD. Boehringer Ingelheim's popular Stiolto Respimat will benefit from FLAME's good will, but GSK's son-of-Advair, Breo, will likely suffer.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel